scholarly journals Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

2005 ◽  
Vol 187 (6) ◽  
pp. 537-543 ◽  
Author(s):  
Robert B. Zipursky ◽  
Hongbin Gu ◽  
Alan I. Green ◽  
Diana O. Perkins ◽  
Mauricio F. Tohen ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Weight Gain ◽  
Time Course ◽  
Atypical Antipsychotics ◽  
First Episode Psychosis ◽  
First Episode ◽  
Episode Psychosis ◽  
Study Completion ◽  
Clinically Significant ◽  
Potentially Clinically Significant

BackgroundSubstantial weight gain is common with many atypical antipsychotics.AimsTo evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol.MethodSurvival analysis assessed time to potentially clinically significant weight gain (⩾7%) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches.ResultsAfter 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001).ConclusionsOlanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.

scholarly journals Weight Gain in First-Episode Psychosis

2003 ◽  
Vol 48 (4) ◽  
pp. 272-276 ◽  
Author(s):  
Jean Addington ◽  
Chrystal Mansley ◽  
Donald Addington
Keyword(s):  
Body Mass Index ◽  
Weight Gain ◽  
Body Mass ◽  
First Episode Psychosis ◽  
First Episode ◽  
First Year ◽  
Optimum Treatment ◽  
Episode Psychosis ◽  
Second Generation Antipsychotics ◽  
Potential Weight

Objective: To examine the extent of weight gain in the first year of treatment in an early psychosis program. Method: Subjects were 114 individuals who had experienced a first episode of psychosis and had completed 1 year in a comprehensive first-episode program. Weight and body mass index were calculated on entry to the program and at 6 and 12 months. Most of the subjects were all being prescribed second-generation antipsychotics. Results: Significant increases in mean weight were observed in these young individuals over the course of the first year of treatment. Conclusions: If we are to work toward optimum treatment for first-episode subjects then potential weight gain needs to be addressed at the beginning of treatment and monitored during treatment.

Effect of Treatment on Weight Gain and Metabolic Abnormalities in Patients with First-Episode Psychosis

2009 ◽  
Vol 43 (9) ◽  
pp. 812-817 ◽  
Author(s):  
Swapna Verma ◽  
Alvin Liew ◽  
Mythily Subramaniam ◽  
Lye Yin Poon
Keyword(s):  
Weight Gain ◽  
Density Lipoprotein ◽  
Female Gender ◽  
Serum Levels ◽  
First Episode Psychosis ◽  
First Episode ◽  
Intervention Programme ◽  
Significant Weight Gain ◽  
Episode Psychosis ◽  
Clinically Significant

Objective: The aim of the present prospective and naturalistic study was to examine the effects of antipsychotic medication on weight and serum levels of lipids, glucose and insulin in first-episode psychosis patients. Method: Fifty-six patients admitted to the Singapore Early Psychosis Intervention Programme participated in this study. They were assessed at baseline (i.e. within 72 h of starting antipsychotics), and 6 months later. Weight (kg) and height (m) were measured and body mass index (BMI) was calculated. Blood samples were taken after a 12 h overnight fast. Choice of antipsychotics was based on the treating physician's clinical decision. Total cumulative Chlorpromazine (CPZ) equivalent of antipsychotic exposure during the 6 months was calculated. Statistical analyses were carried out for comparisons between baseline and 6 months, and for the two outcome event groups of ≥7% versus <7% weight gain. Where appropriate, confounders were controlled. Results and conclusion: There were significant increases in BMI, serum levels of triglyceride, low-density lipoprotein and total cholesterol from baseline to 6 months. Mean increase in weight was 6.2±7.0 kg (p < 0.05) and 65% of the patients had clinically significant weight gain (i.e. ≥7% increase from baseline). On logistic regression lower baseline BMI, female gender, and younger age, were associated with clinically significant weight gain.

scholarly journals Circulating lipids associate with future weight gain in individuals with an at-risk mental state and in first-episode psychosis

2020 ◽  
Author(s):  
Santosh Lamichhane ◽  
Alex M. Dickens ◽  
Partho Sen ◽  
Heikki Laurikainen ◽  
Jaana Suvisaari ◽  
...  
Keyword(s):  
At Risk ◽  
Weight Gain ◽  
High Risk ◽  
Psychotic Disorders ◽  
First Episode Psychosis ◽  
Molecular Signature ◽  
First Episode ◽  
Baseline Serum ◽  
Average Life Span ◽  
Episode Psychosis

AbstractPatients with schizophrenia have a lower than average life span, largely due to the increased prevalence of cardiometabolic co-morbidities. Identification of individuals with psychotic disorders with a high risk of rapid weight gain, and the associated development of metabolic complications, is an unmet need as regards public health. Here, we applied mass spectrometry-based lipidomics in a prospective study comprising 48 controls (CTR), 44 first-episode psychosis (FEP) patients and 22 individuals at clinical-high-risk (CHR) for psychosis, from two study centers (Turku/Finland and London/UK). Baseline serum samples were analyzed by lipidomics, while body mass index (BMI) was assessed at baseline and after 12 months. We found that baseline triacylglycerols with low double bond counts and carbon numbers were positively associated with the change in BMI at follow-up. In addition, a molecular signature comprised of two triacylglycerols (TG(48:0) and TG(45:0)), was predictive of weight gain in individuals with a psychotic disorder, with an area under the receiver operating characteristic curve (AUROC) of 0.74 (95% CI: 0.60–0.85). When independently tested in the CHR group, this molecular signature predicted said weight change with AUROC = 0.73 (95% CI: 0.61–0.83). We conclude that molecular lipids may serve as a predictor of weight gain in psychotic disorders in at-risk individuals, and may thus provide a useful marker for identifying individuals who are most prone to developing cardiometabolic co-morbidities.

scholarly journals The Psychology of Food Cravings in Patients With First-Episode Psychosis

2020 ◽  
Vol 11 ◽  
Author(s):  
Young-Hyuk Kim ◽  
Seunghyong Ryu ◽  
Hee-Jung Nam ◽  
Mina Kim ◽  
Min Jhon ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Perceived Stress ◽  
First Episode Psychosis ◽  
Psychological Characteristics ◽  
First Episode ◽  
Loss Of Control ◽  
Food Cravings ◽  
Significant Weight Gain ◽  
Episode Psychosis

Objectives: Food cravings may cause weight gain in patients with schizophrenia. This study investigated psychological characteristics associated with food cravings in patients with first-episode psychosis.Methods: This study analyzed data from a clinical cohort of first-episode psychosis patients taking antipsychotics for 3 months or less. The strength of food cravings was measured using the General Food Cravings Questionnaire-Trait (G-FCQ-T). Psychological characteristics and psychiatric symptoms were investigated with the Positive and Negative Symptom Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Social and Occupational Functioning Assessment Scale, Rosenberg Self-Esteem Scale (RSES), and Perceived Stress Scale (PSS). Clinical characteristics were compared according to significant weight gain (≥10% increase in body weight compared to baseline) over 3 months. Associations between the G-FCQ-T and other psychiatric scales were investigated. We conducted sex-stratified analyses.Results: In total, 182 patients (78 males and 104 females) with first-episode psychosis were enrolled in this study. In females, the G-FCQ-T total score at baseline was associated with baseline body weight and significant weight gain over 3 months. The PSS scales were significantly associated the G-FCQ-T total and all subscale scores in female participants. Scores on the RSES and CDSS were significantly associated with the G-FCQ-T total score and with the preoccupation and loss of control subscale scores. The PANSS negative and general subscales were significantly associated with the positive outcome expectancy and loss of control subscales of the G-FCQ-T, respectively. In males, the only significant association was between the loss of control subscale and RSES scores. Linear regression analysis showed significant associations of PSS scores with the total and all subscale scores of the G-FCQ-T despite the loss of significance for other variables.Conclusion: These results indicate that the food cravings in patients with first-episode psychosis, which were associated with weight gain, were influenced by perceived stress in females. To reduce food cravings in female patients with schizophrenia, interventions aimed at perceived stress should be considered.

Clinical correlates of weight gain in first episode psychosis patients treated with olanzapine

2003 ◽  
Vol 60 (1) ◽  
pp. 372 ◽  
Author(s):  
R. Zipursky ◽  
H. Gu ◽  
A.I. Green ◽  
F. Centorrina ◽  
I. Glick ◽  
...  
Keyword(s):  
Weight Gain ◽  
First Episode Psychosis ◽  
First Episode ◽  
Clinical Correlates ◽  
Episode Psychosis

scholarly journals Different Effects of Typical and Atypical Antipsychotics on Grey Matter in First Episode Psychosis: the ÆSOP Study

2005 ◽  
Vol 30 (4) ◽  
pp. 765-774 ◽  
Author(s):  
Paola Dazzan ◽  
Kevin D Morgan ◽  
Ken Orr ◽  
Gerard Hutchinson ◽  
Xavier Chitnis ◽  
...  
Keyword(s):  
Grey Matter ◽  
Atypical Antipsychotics ◽  
First Episode Psychosis ◽  
First Episode ◽  
Episode Psychosis ◽  
Typical And Atypical Antipsychotics

scholarly journals Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis

2020 ◽  
Author(s):  
Santosh Lamichhane ◽  
Alex M Dickens ◽  
Partho Sen ◽  
Heikki Laurikainen ◽  
Faith Borgan ◽  
...  
Keyword(s):  
At Risk ◽  
Weight Gain ◽  
High Risk ◽  
Psychotic Disorders ◽  
First Episode Psychosis ◽  
Molecular Signature ◽  
First Episode ◽  
Baseline Serum ◽  
Average Life Span ◽  
Episode Psychosis

Abstract Patients with schizophrenia have a lower than average life span, largely due to the increased prevalence of cardiometabolic comorbidities. There is an unmet public health need to identify individuals with psychotic disorders who have a high risk of rapid weight gain and who are at risk of developing metabolic complications. Here, we applied mass spectrometry-based lipidomics in a prospective study comprising 48 healthy controls (CTR), 44 first-episode psychosis (FEP) patients, and 22 individuals at clinical high risk (CHR) for psychosis, from 2 study centers (Turku, Finland and London, UK). Baseline serum samples were analyzed using lipidomics, and body mass index (BMI) was assessed at baseline and after 12 months. We found that baseline triacylglycerols (TGs) with low double-bond counts and carbon numbers were positively associated with the change in BMI at follow-up. In addition, a molecular signature comprised of 2 TGs (TG[48:0] and TG[45:0]) was predictive of weight gain in individuals with a psychotic disorder, with an area under the receiver operating characteristic curve (AUROC) of 0.74 (95% CI: 0.60–0.85). When independently tested in the CHR group, this molecular signature predicted said weight change with AUROC = 0.73 (95% CI: 0.61–0.83). We conclude that molecular lipids may serve as a predictor of weight gain in psychotic disorders in at-risk individuals and may thus provide a useful marker for identifying individuals who are most prone to developing cardiometabolic comorbidities.

Weight gain in first-episode psychosis over three years

2006 ◽  
Vol 86 (1-3) ◽  
pp. 335-336 ◽  
Author(s):  
Jean Addington ◽  
Huma Saeedi ◽  
Donald Addington
Keyword(s):  
Weight Gain ◽  
First Episode Psychosis ◽  
First Episode ◽  
Episode Psychosis
Sign in / Sign up

Export Citation Format

Share Document